Home LiteratureArticle Details
PMID: 17950310 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Pathogenic mechanisms of pulmonary arterial hypertension.

Journal of molecular and cellular cardiology ·Vol. 44 ·No. 1 ·2008-01-00 ·Pages 14-30

Chan SY, Loscalzo J

Abstract

Pulmonary arterial hypertension (PAH) is a complex disease that causes significant morbidity and mortality and is clinically characterized by an increase in pulmonary vascular resistance. The histopathology is marked by vascular proliferation/fibrosis, remodeling, and vessel obstruction. Development of PAH involves the complex interaction of multiple vascular effectors at all anatomic levels of the arterial wall. Subsequent vasoconstriction, thrombosis, and inflammation ensue, leading to vessel wall remodeling and cellular hyperproliferation as the hallmarks of severe disease. These processes are influenced by genetic predisposition as well as diverse endogenous and exogenous stimuli. Recent studies have provided a glimpse at certain molecular pathways that contribute to pathogenesis; these have led to the identification of attractive targets for therapeutic intervention. We will review our current understanding of the mechanistic underpinnings of the genetic and exogenous/acquired triggers of PAH. The resulting imbalance of vascular effectors provoking pathogenic vascular changes will also be discussed, with an emphasis on common and overarching regulatory pathways that may relate to the primary triggers of disease. The current conceptual framework should allow for future studies to refine our understanding of the molecular pathogenesis of PAH and improve the therapeutic regimen for this disease.

MeSH Terms
Animals Genetic Predisposition to Disease Humans Hypertension, Pulmonary/genetics,pathology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Chan Stephen Y
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Loscalzo Joseph
References (235)
235 references, click to expand
  1. Lung biopsy specimens in the evaluation of pulmonary vascular disease.
    Chest. 1980 May;77(5):614-25 PMID: 7363679
  2. The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies.
    Adv Exp Med Biol. 2003;543:293-322 PMID: 14713130
  3. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.
    N Engl J Med. 1992 Jul 9;327(2):70-5 PMID: 1603138
  4. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
    N Engl J Med. 2004 Feb 26;350(9):886-95 PMID: 14985486
  5. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF).
    Peptides. 1984 Mar-Apr;5(2):325-8 PMID: 6206481
  6. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.
    J Clin Invest. 1998 Mar 1;101(5):927-34 PMID: 9486960
  7. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.
    Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L665-72 PMID: 12959926
  8. No role for kaposi sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension.
    Pediatr Pulmonol. 2006 Feb;41(2):122-5 PMID: 16369926
  9. Hypoxic pulmonary vasoconstriction.
    J Appl Physiol (1985). 2005 Jan;98(1):390-403 PMID: 15591309
  10. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2005 Dec 15;172(12):1581-5 PMID: 16192453
  11. Chemokine RANTES in severe pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2002 Feb 15;165(4):534-9 PMID: 11850348
  12. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
    Chin Med J (Engl). 2007 Jan 5;120(1):22-9 PMID: 17254483
  13. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease.
    Respir Res. 2001;2(5):280-5 PMID: 11686897
  14. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension.
    Thorax. 2004 May;59(5):446-8 PMID: 15115879
  15. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension.
    J Infect Dis. 2005 Mar 1;191(5):743-5 PMID: 15688289
  16. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells.
    Proc Soc Exp Biol Med. 1992 Feb;199(2):165-70 PMID: 1741408
  17. Pulmonary arterial hypertension.
    N Engl J Med. 2004 Oct 14;351(16):1655-65 PMID: 15483284
  18. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
    Circ J. 2006 Feb;70(2):174-8 PMID: 16434811
  19. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
    Circ Res. 2006 Feb 3;98(2):209-17 PMID: 16357305
  20. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia.
    Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1111-9 PMID: 9563727
  21. Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension.
    Life Sci. 1995;57(19):1771-9 PMID: 7475919
  22. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.
    Science. 2001 Sep 28;293(5539):2449-52 PMID: 11498544
  23. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning.
    FASEB J. 2000 Apr;14(5):805-14 PMID: 10744637
  24. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
    Hum Mutat. 2006 Feb;27(2):212-3 PMID: 16429403
  25. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects.
    Clin Physiol. 1993 Nov;13(6):677-85 PMID: 8119061
  26. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice.
    Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13248-53 PMID: 12237402
  27. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.
    Circ Res. 2006 Aug 4;99(3):240-7 PMID: 16840720
  28. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension.
    Am J Physiol. 1992 May;262(5 Pt 1):L614-20 PMID: 1534203
  29. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.
    Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15215-20 PMID: 11752464
  30. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.
    J Clin Invest. 1996 Jun 1;97(11):2491-8 PMID: 8647941
  31. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin.
    Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11728-32 PMID: 7972131
  32. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
    Circulation. 2005 Feb 8;111(5):607-13 PMID: 15699281
  33. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension.
    Circulation. 2004 May 4;109(17):2150-5 PMID: 15078799
  34. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.
    N Engl J Med. 1993 Jun 17;328(24):1732-9 PMID: 8497283
  35. BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways.
    Am J Physiol Lung Cell Mol Physiol. 2005 Feb;288(2):L370-8 PMID: 15516492
  36. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.
    Am J Respir Crit Care Med. 1998 Jan;157(1):219-29 PMID: 9445303
  37. Upregulation of collagens detected by gene array in a model of flow-induced pulmonary vascular remodeling.
    Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H414-22 PMID: 11788387
  38. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.
    Nat Med. 2002 Dec;8(12):1383-9 PMID: 12426562
  39. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.
    Am J Respir Crit Care Med. 2007 Jun 15;175(12):1280-9 PMID: 17413127
  40. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
    J Cardiovasc Pharmacol. 2007 Feb;49(2):85-9 PMID: 17312448
  41. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.
    Circ Res. 2004 Apr 30;94(8):1109-14 PMID: 15031260
  42. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae.
    J Biol Chem. 1996 Mar 15;271(11):6518-22 PMID: 8626455
  43. Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension.
    J Pediatr Surg. 2007 May;42(5):758-64 PMID: 17502178
  44. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.
    Hum Pathol. 1997 Apr;28(4):434-42 PMID: 9104943
  45. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension.
    J Pathol. 1998 Jul;185(3):313-8 PMID: 9771486
  46. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype.
    Mol Med Today. 1999 Jan;5(1):40-6 PMID: 10088131
  47. Absence of human herpesvirus 8 in lung tissues from Japanese patients with primary pulmonary hypertension.
    Respir Med. 2004 Dec;98(12):1231-2 PMID: 15588046
  48. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells.
    Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1059-67 PMID: 17030903
  49. CX(3)C chemokine fractalkine in pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2002 May 15;165(10):1419-25 PMID: 12016106
  50. Sildenafil in the treatment of pulmonary hypertension.
    Vasc Health Risk Manag. 2006;2(4):411-22 PMID: 17323595
  51. Genetic basis of pulmonary arterial hypertension: current understanding and future directions.
    J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S PMID: 15194176
  52. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research.
    Am J Respir Crit Care Med. 2001 Dec 1;164(11):2016-9 PMID: 11739128
  53. Simvastatin enhances bone morphogenetic protein receptor type II expression.
    Biochem Biophys Res Commun. 2006 Jan 6;339(1):59-64 PMID: 16297860
  54. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy.
    Am Rev Respir Dis. 1992 May;145(5):1196-200 PMID: 1586065
  55. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
    Am J Respir Crit Care Med. 2003 Aug 15;168(4):487-93 PMID: 12773327
  56. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity.
    Am Rev Respir Dis. 1993 Aug;148(2):519-22 PMID: 8342919
  57. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
    Hum Mutat. 2006 Feb;27(2):121-32 PMID: 16429395
  58. Scleroderma. Clinical problems. The lungs.
    Rheum Dis Clin North Am. 1996 Nov;22(4):825-40 PMID: 8923598
  59. Primary pulmonary hypertension in HIV infection.
    Chest. 1991 Nov;100(5):1268-71 PMID: 1935280
  60. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.
    Circulation. 2001 Aug 14;104(7):790-5 PMID: 11502704
  61. Oxidative stress in severe pulmonary hypertension.
    Am J Respir Crit Care Med. 2004 Mar 15;169(6):764-9 PMID: 14701708
  62. Shear stress paradigm for perinatal fractal arterial network remodeling in lambs with pulmonary hypertension and increased pulmonary blood flow.
    Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3006-18 PMID: 17308003
  63. Atrial septal defects in the adult: recent progress and overview.
    Circulation. 2006 Oct 10;114(15):1645-53 PMID: 17030704
  64. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia.
    Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1241-7 PMID: 15286002
  65. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas.
    Am J Pathol. 2001 Mar;158(3):833-9 PMID: 11238032
  66. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.
    J Pathol. 2001 Oct;195(3):367-74 PMID: 11673836
  67. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
    Am J Hum Genet. 2001 Jan;68(1):92-102 PMID: 11115378
  68. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.
    N Engl J Med. 2001 Aug 2;345(5):325-34 PMID: 11484689
  69. Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.
    Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12331-6 PMID: 14512515
  70. Rho-kinase is an important therapeutic target in cardiovascular medicine.
    Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1767-75 PMID: 16002741
  71. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells.
    Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L993-1004 PMID: 16815889
  72. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease.
    Circulation. 2003 Oct 14;108(15):1839-44 PMID: 14530202
  73. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene.
    Circulation. 2007 Mar 13;115(10):1260-8 PMID: 17309917
  74. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension.
    Clin Sci (Lond). 1999 Jan;96(1):33-9 PMID: 9857104
  75. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
    Circulation. 2007 Jun 12;115(23):2957-68 PMID: 17515463
  76. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
    Circulation. 2002 Apr 9;105(14):1672-8 PMID: 11940546
  77. Protective role of angiopoietin-1 in experimental pulmonary hypertension.
    Circ Res. 2003 May 16;92(9):984-91 PMID: 12690034
  78. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.
    Pharmacol Res. 2007 Jan;55(1):64-71 PMID: 17127075
  79. Gender issues in pulmonary vascular disease.
    Clin Chest Med. 2004 Jun;25(2):373-7 PMID: 15099896
  80. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension.
    Respirology. 2006 Mar;11(2):158-63 PMID: 16548900
  81. Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels.
    Respir Res. 2000;1(1):40-8 PMID: 11667964
  82. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.
    Am J Pathol. 2004 Jan;164(1):253-62 PMID: 14695338
  83. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
    Cell. 2003 Jun 13;113(6):685-700 PMID: 12809600
  84. The tantalizing triplet of pulmonary hypertension-BMP receptors, serotonin receptors, and angiopoietins.
    Cardiovasc Res. 2003 Dec 1;60(3):465-7 PMID: 14659791
  85. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor.
    Nat Med. 2000 Jun;6(6):698-702 PMID: 10835689
  86. Primary pulmonary hypertension and cirrhosis: are they related?
    Am Rev Respir Dis. 1983 Apr;127(4):437-41 PMID: 6838050
  87. Caveolae, lipid rafts, and vascular disease.
    Trends Cardiovasc Med. 2005 Apr;15(3):92-6 PMID: 16039968
  88. Expression of human herpesvirus 8 in primary pulmonary hypertension.
    N Engl J Med. 2003 Sep 18;349(12):1113-22 PMID: 13679525
  89. Pulmonary arterial hypertension.
    Circulation. 2006 Sep 26;114(13):1417-31 PMID: 17000921
  90. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension.
    N Engl J Med. 1983 Jul 14;309(2):77-80 PMID: 6855869
  91. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase.
    Am J Physiol Lung Cell Mol Physiol. 2004 Oct;287(4):L656-64 PMID: 14977625
  92. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Clin Chest Med. 2007 Mar;28(1):117-25, viii PMID: 17338931
  93. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization.
    Circ Res. 2006 Apr 14;98(7):931-8 PMID: 16527989
  94. Lung disease in systemic sclerosis (scleroderma).
    Baillieres Clin Rheumatol. 1993 Feb;7(1):79-97 PMID: 8519079
  95. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C.
    Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L472-9 PMID: 17468135
  96. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin.
    Circ Res. 2004 Sep 17;95(6):579-86 PMID: 15297378
  97. Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis.
    Heart. 1997 Oct;78(4):390-5 PMID: 9404257
  98. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.
    Circ Res. 2006 May 26;98(10):1323-30 PMID: 16614302
  99. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension.
    Cardiovasc Res. 2002 Aug 1;55(2):361-8 PMID: 12123775
  100. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization.
    Chest. 1989 Nov;96(5):1050-3 PMID: 2805835
  101. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.
    Blood. 2003 Feb 15;101(4):1257-61 PMID: 12393669
  102. Carbon monoxide reverses established pulmonary hypertension.
    J Exp Med. 2006 Sep 4;203(9):2109-19 PMID: 16908624
  103. Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1.
    Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1209-21 PMID: 12003776
  104. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat.
    Circ Res. 2000 Jun 23;86(12):1224-9 PMID: 10864912
  105. Cellular and molecular pathobiology of pulmonary arterial hypertension.
    J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S PMID: 15194174
  106. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.
    N Engl J Med. 1995 Jul 27;333(4):214-21 PMID: 7540722
  107. Haemodynamic sequelae of pulmonary fibrosis following intratracheal bleomycin in rats.
    Cardiovasc Res. 1992 Apr;26(4):401-8 PMID: 1379125
  108. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin.
    J Clin Invest. 1994 Sep;94(3):1163-71 PMID: 8083356
  109. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats.
    Circulation. 2003 Apr 22;107(15):2037-44 PMID: 12695303
  110. Primary pulmonary hypertension.
    Thorax. 1999 Dec;54(12):1107-18 PMID: 10567632
  111. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor.
    Br J Pharmacol. 1999 Oct;128(3):730-4 PMID: 10516655
  112. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
    Circulation. 2007 Mar 13;115(10):1275-84 PMID: 17339547
  113. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin.
    Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L463-71 PMID: 17545489
  114. [Impact of hydrogen sulfide donor on experimental pulmonary hypertension induced by high pulmonary flow and endogenous carbon monoxide/heme oxygenase pathway].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Apr 18;38(2):135-9 PMID: 16617353
  115. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935.
    Circ Res. 2001 Dec 7;89(12):1231-9 PMID: 11739290
  116. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.
    Circ Res. 2005 May 27;96(10):1053-63 PMID: 15845886
  117. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.
    J Clin Invest. 1995 Apr;95(4):1798-807 PMID: 7706486
  118. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.
    Am J Physiol. 1995 Jun;268(6 Pt 1):L1047-51 PMID: 7541947
  119. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.
    J Clin Invest. 2000 Jan;105(1):21-34 PMID: 10619858
  120. Attenuated K+ channel gene transcription in primary pulmonary hypertension.
    Lancet. 1998 Mar 7;351(9104):726-7 PMID: 9504523
  121. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.
    J Leukoc Biol. 2006 Jan;79(1):192-201 PMID: 16282533
  122. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.
    Nat Genet. 2000 Sep;26(1):81-4 PMID: 10973254
  123. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.
    Genet Med. 2005 Mar;7(3):169-74 PMID: 15775752
  124. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.
    Chest. 1996 Dec;110(6):1515-9 PMID: 8989070
  125. Increased plasma serotonin in primary pulmonary hypertension.
    Am J Med. 1995 Sep;99(3):249-54 PMID: 7653484
  126. Eisenmenger syndrome and atrial septal defect: nature or nurture?
    Can J Cardiol. 2006 Nov;22(13):1133-6 PMID: 17102831
  127. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells.
    FASEB J. 2007 Nov;21(13):3640-52 PMID: 17567571
  128. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
    Chest. 2001 Sep;120(3):801-8 PMID: 11555513
  129. Prostanoid therapy for pulmonary arterial hypertension.
    Clin Chest Med. 2007 Mar;28(1):127-42; ix PMID: 17338932
  130. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
    Am J Hum Genet. 2000 Sep;67(3):737-44 PMID: 10903931
  131. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension.
    Am J Respir Crit Care Med. 2006 Nov 1;174(9):1025-33 PMID: 16917117
  132. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction.
    Circulation. 1987 Nov;76(5):1037-42 PMID: 3664992
  133. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L872-8 PMID: 17142350
  134. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.
    Am J Pathol. 1999 Aug;155(2):411-9 PMID: 10433934
  135. The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats.
    Biochem Biophys Res Commun. 2003 Mar 21;302(4):810-6 PMID: 12646242
  136. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.
    Circulation. 2002 Jul 2;106(1):57-62 PMID: 12093770
  137. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin.
    Am J Med. 1990 Jul;89(1):117-20 PMID: 2368783
  138. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
    N Engl J Med. 2006 Feb 9;354(6):579-87 PMID: 16467545
  139. HIV-associated pulmonary hypertension.
    AIDS Clin Care. 2001 Jun;13(6):53-5, 59 PMID: 11710309
  140. Hypoxic pulmonary vasoconstriction.
    Gen Pharmacol. 1999 Oct;33(4):289-97 PMID: 10523066
  141. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats.
    Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L284-90 PMID: 16155085
  142. Idiopathic pulmonary arterial hypertension in Dutch Caucasian patients is not associated with human herpes virus-8 infection.
    Respir Med. 2007 Apr;101(4):854-6 PMID: 17011770
  143. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling.
    Int J Exp Pathol. 2006 Dec;87(6):463-74 PMID: 17222214
  144. Divergent effects of BMP-2 on gene expression in pulmonary artery smooth muscle cells from normal subjects and patients with idiopathic pulmonary arterial hypertension.
    Exp Lung Res. 2005 Oct;31(8):783-806 PMID: 16368652
  145. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension.
    Circ Res. 2005 Sep 16;97(6):596-604 PMID: 16109920
  146. Genetic clues to the cause of primary pulmonary hypertension.
    N Engl J Med. 2001 Aug 2;345(5):367-71 PMID: 11484696
  147. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD.
    Respir Med. 2003 Dec;97(12):1282-8 PMID: 14682408
  148. Stimulant-induced pulmonary toxicity.
    Chest. 1995 Oct;108(4):1140-9 PMID: 7555128
  149. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
    Circulation. 2007 May 1;115(17):2331-9 PMID: 17438150
  150. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells.
    FASEB J. 2007 Sep;21(11):2725-34 PMID: 17504974
  151. Pathobiology of pulmonary hypertension. Extracellular matrix.
    Clin Chest Med. 2001 Sep;22(3):433-49, viii PMID: 11590839
  152. Elastase and the pathobiology of unexplained pulmonary hypertension.
    Chest. 1998 Sep;114(3 Suppl):213S-224S PMID: 9741572
  153. BMP type II receptor is required for gastrulation and early development of mouse embryos.
    Dev Biol. 2000 May 1;221(1):249-58 PMID: 10772805
  154. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1182-92 PMID: 17277049
  155. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
    Circ Res. 2007 Mar 30;100(6):923-9 PMID: 17332430
  156. Controlling TGF-beta signaling.
    Genes Dev. 2000 Mar 15;14(6):627-44 PMID: 10733523
  157. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.
    Circulation. 1996 Nov 1;94(9):2216-20 PMID: 8901674
  158. Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2.
    J Appl Physiol Respir Environ Exerc Physiol. 1980 Jul;49(1):107-12 PMID: 6995413
  159. Pulmonary hypertension: cellular and molecular mechanisms.
    Chest. 2005 Dec;128(6 Suppl):565S-571S PMID: 16373828
  160. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.
    J Clin Invest. 1999 Apr;103(8):R23-9 PMID: 10207174
  161. Acetylcholine and bradykinin relax intrapulmonary arteries by acting on endothelial cells: role in lung vascular diseases.
    Science. 1981 Sep 18;213(4514):1376-9 PMID: 7268440
  162. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
    N Engl J Med. 2001 Aug 2;345(5):319-24 PMID: 11484688
  163. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins.
    Biochem Biophys Res Commun. 2005 Aug 12;333(4):1107-15 PMID: 15979050
  164. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells.
    Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L740-54 PMID: 12740218
  165. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension.
    Circ Res. 2001 Jan 19;88(1):E2-E11 PMID: 11139485
  166. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension.
    Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13861-6 PMID: 15358862
  167. Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension.
    J Clin Invest. 1990 Nov;86(5):1459-64 PMID: 2243124
  168. The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro.
    Vascul Pharmacol. 2006 Jan;44(1):50-9 PMID: 16271518
  169. Inhaled nitric oxide therapy in adults.
    N Engl J Med. 2005 Dec 22;353(25):2683-95 PMID: 16371634
  170. Clinical classification of pulmonary hypertension.
    J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S PMID: 15194173
  171. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
    J Biol Chem. 2005 Jul 1;280(26):24443-50 PMID: 15883158
  172. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.
    Hum Mol Genet. 2002 Jun 15;11(13):1517-25 PMID: 12045205
  173. Signaling molecules in nonfamilial pulmonary hypertension.
    N Engl J Med. 2003 Feb 6;348(6):500-9 PMID: 12571257
  174. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.
    Am J Respir Crit Care Med. 2006 Aug 15;174(4):437-45 PMID: 16728715
  175. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L694-702 PMID: 16782755
  176. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation.
    Circ Res. 1996 Dec;79(6):1131-42 PMID: 8943951
  177. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta.
    Circ Res. 2003 Oct 3;93(7):656-63 PMID: 12970114
  178. Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension.
    Respiration. 2008;75(2):155-7 PMID: 17124380
  179. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia.
    J Clin Invest. 1999 Jan;103(2):291-9 PMID: 9916141
  180. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.
    Heart. 2005 Mar;91(3):391-2 PMID: 15710736
  181. Specific bone morphogenic protein receptor II mutations found in primary pulmonary hypertension cause different biochemical phenotypes in vitro.
    Chest. 2002 Mar;121(3 Suppl):83S PMID: 11893707
  182. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.
    Am J Hematol. 1999 Feb;60(2):130-5 PMID: 9929105
  183. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.
    Mayo Clin Proc. 1996 Jun;71(6):543-51 PMID: 8642882
  184. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.
    FASEB J. 2001 Feb;15(2):427-38 PMID: 11156958
  185. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture.
    Am J Physiol. 1994 Jan;266(1 Pt 1):L46-52 PMID: 8304469
  186. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
    Circ Res. 2004 Feb 20;94(3):385-93 PMID: 14670839
  187. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.
    J Clin Invest. 2005 Jun;115(6):1479-91 PMID: 15931388
  188. Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension.
    Chest. 2005 Dec;128(6 Suppl):633S-642S PMID: 16373885
  189. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats.
    Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1775-84 PMID: 14726295
  190. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Blood. 2007 Apr 1;109(7):3088-98 PMID: 17158223
  191. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.
    FASEB J. 2005 Jul;19(9):1178-80 PMID: 15897232
  192. Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension.
    Am J Respir Crit Care Med. 2007 Oct 15;176(8):819-24 PMID: 17641158
  193. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.
    Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11375-80 PMID: 12177436
  194. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension.
    Chest. 2006 Mar;129(3):696-705 PMID: 16537870
  195. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.
    Nat Med. 2002 Oct;8(10):1129-35 PMID: 12244304
  196. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
    J Cardiovasc Pharmacol. 2006 Dec;48(6):280-5 PMID: 17204906
  197. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms.
    Am J Physiol. 1994 Nov;267(5 Pt 2):H1921-7 PMID: 7526714
  198. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models.
    Arterioscler Thromb Vasc Biol. 2006 May;26(5):1008-14 PMID: 16456096
  199. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.
    Prog Cardiovasc Dis. 2002 Nov-Dec;45(3):173-202 PMID: 12525995
  200. Gene transfer of a TIE2 receptor antagonist prevents pulmonary hypertension in rodents.
    J Thorac Cardiovasc Surg. 2005 Feb;129(2):268-76 PMID: 15678035
  201. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.
    J Med Genet. 2000 Oct;37(10):741-5 PMID: 11015450
  202. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
    Chest. 2006 Dec;130(6):1657-63 PMID: 17166979
  203. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.
    Am J Physiol Cell Physiol. 2007 May;292(5):C1837-53 PMID: 17267549
  204. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity.
    Arthritis Res Ther. 2006;8(4):R104 PMID: 16813666
  205. Sildenafil citrate therapy for pulmonary arterial hypertension.
    N Engl J Med. 2005 Nov 17;353(20):2148-57 PMID: 16291984
  206. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.
    J Clin Invest. 2001 Oct;108(8):1141-50 PMID: 11602621
  207. Suppression of type II bone morphogenic protein receptor in vascular smooth muscle induces pulmonary arterial hypertension in transgenic mice.
    Chest. 2005 Dec;128(6 Suppl):553S PMID: 16373822
  208. Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension.
    Proc Soc Exp Biol Med. 1988 Jan;187(1):26-32 PMID: 3124119
  209. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling.
    Chest. 2002 Dec;122(6 Suppl):326S-334S PMID: 12475810
  210. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine.
    Cardiovasc Surg. 2002 Apr;10(2):138-45 PMID: 11888743
  211. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    J Rheumatol. 2007 May;34(5):1005-11 PMID: 17444586
  212. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.
    Am J Respir Crit Care Med. 1999 Jun;159(6):1925-32 PMID: 10351941
  213. The serotonin pathway in pulmonary hypertension.
    Arch Mal Coeur Vaiss. 2006 Jun;99(6):621-5 PMID: 16878724
  214. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
    Arterioscler Thromb Vasc Biol. 2007 May;27(5):1072-8 PMID: 17347486
  215. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
    J Clin Invest. 2003 May;111(9):1339-46 PMID: 12727925
  216. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Circulation. 2005 Jul 26;112(4):553-62 PMID: 16027259
  217. Signaling and functions of angiopoietin-1 in vascular protection.
    Circ Res. 2006 Apr 28;98(8):1014-23 PMID: 16645151
  218. BMP signaling controls PASMC KV channel expression in vitro and in vivo.
    Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L841-8 PMID: 16339782
  219. [A case of chronic thromboembolic pulmonary hypertension based on essential thrombocythemia].
    Nihon Kokyuki Gakkai Zasshi. 2002 Jul;40(7):574-8 PMID: 12382421
  220. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology.
    Mol Syst Biol. 2007;3:124 PMID: 17625512
  221. Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1526-42 PMID: 17337506
  222. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
    Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8 PMID: 12406854
  223. Cardiopulmonary assessment in beta-thalassemia major.
    Chest. 1990 Nov;98(5):1138-42 PMID: 2225958
  224. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.
    Circ Res. 2006 Mar 31;98(6):818-27 PMID: 16497988
  225. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension.
    Microcirculation. 2006 Dec;13(8):615-32 PMID: 17085423
  226. Primary pulmonary hypertension: insights into pathogenesis from epidemiology.
    Chest. 1998 Sep;114(3 Suppl):184S-194S PMID: 9741567
  227. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.
    Circulation. 2002 Jan 29;105(4):516-21 PMID: 11815437
  228. Right ventricular cardiac dysfunction in beta-thalassemia major.
    Am J Dis Child. 1987 Jan;141(1):93-6 PMID: 3788890
  229. NO contest: nitrite versus S-nitroso-hemoglobin.
    Circ Res. 2004 Apr 16;94(7):851-5 PMID: 15087423
  230. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
    Am J Respir Cell Mol Biol. 2005 Nov;33(5):438-46 PMID: 16002577
  231. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations.
    J Gastroenterol. 2001 Mar;36(3):181-6 PMID: 11291881
  232. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension.
    Am J Respir Crit Care Med. 1999 Feb;159(2):361-4 PMID: 9927344
  233. Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia.
    Aust N Z J Med. 1996 Dec;26(6):852-3 PMID: 9028525
  234. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.
    N Engl J Med. 1996 Aug 29;335(9):609-16 PMID: 8692238
  235. Genetic association of the serotonin transporter in pulmonary arterial hypertension.
    Am J Respir Crit Care Med. 2006 Apr 1;173(7):793-7 PMID: 16399993
Article Info
Journal
Journal of molecular and cellular cardiology
Abbr.
J Mol Cell Cardiol
ISSN
1095-8584
Published
2008-01-00
Epub
2007-00-20
Pages
14-30
Language
English
Region
England
NLM ID
0262322
PMCID
PMC2234575
Subset
IM
Grants
NHLBI NIH HHS · N01 HV028178 · United States
NHLBI NIH HHS · HV28718 · United States
NHLBI NIH HHS · R01 HL061795 · United States
NHLBI NIH HHS · R01 HL061795-10 · United States
NHLBI NIH HHS · R37 HL061795 · United States
NHLBI NIH HHS · HL81587 · United States
NHLBI NIH HHS · HL61795 · United States
NHLBI NIH HHS · P01 HL081587-030002 · United States
NHLBI NIH HHS · P01 HL081587 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]